Fundraising Fox

Todd Foley

Investor

Managing Director at MPM BioImpact · Managing Director at MPM Capital

Boston, Massachusetts

FoundedAktis OncologyChiasmaClinical inkCrossbow TherapeuticsEntrada Therapeutics, Inc.Moat Biotechnology

About

Managing Director who joined the firm in 1999. Serves as Chairman of multiple portfolio company boards and has guided significant M&A outcomes including Semma Therapeutics acquisition by Vertex for $950M and Selexys acquisition by Novartis for $665M.

Experience

  1. MPM BioImpactManaging Directorcurrent1999 — present
  2. GenentechBusiness Development Intern1998
  3. Arthur D. LittleAnalyst1994 — 1997

Education

  1. Harvard Business SchoolMBA1997 — 1999
  2. Massachusetts Institute of TechnologyBS, Chemistry1990 — 1994
  3. Guilford High Schoolhigh school1986 — 1990

Skills & more

Venture Capital44Corporate Development20Private Equity16Due Diligence14Biotechnology11

From Todd's professional profile.

Same school

Shared employers

Deals · 7

Moat BiotechnologyBoard seat

via MPM BioImpact · filed Oct 2025 · $15.6M raise

Crossbow TherapeuticsBoard seat

via MPM BioImpact · filed Sep 2025 · $80M raise

Firefly Bio, Inc.Board seat

via MPM BioImpact · filed Mar 2024 · $72M raise

Entrada Therapeutics, Inc.Board seat

via MPM BioImpact · filed Apr 2021 · $116.2M raise

HotKnot Therapeutics, Inc.Board seat

via MPM BioImpact · filed Feb 2021 · $72M raise

Tetherex Pharmaceuticals CorpBoard seat

via MPM BioImpact · filed Dec 2020

Clinical inkBoard seat

via MPM BioImpact · filed Dec 2017 · $2.5M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at MPM BioImpact